高铁与低铁环境对成骨细胞hFOB1.19膜铁转运蛋白1表达的影响

被引：3

作者：

赵国阳 ^{[1
]}

张伟 ^{[1
]}

何银锋 ^{[1
]}

李光飞 ^{[1
]}

林华 ^{[2
]}

徐又佳 ^{[1
]}

机构：

[1] 苏州大学附属第二医院骨科

[2] 南京大学医学院附属鼓楼医院骨病中心

来源：

中华骨质疏松和骨矿盐疾病杂志 | 2012年 / 5卷 / 04期

关键词：

成骨细胞; 铁代谢; 膜铁转运蛋白;

D O I：

暂无

中图分类号：

R363 [病理生理学];

学科分类号：

100103 [病原生物学];

摘要：

目的观察细胞培养液中加入铁离子或铁离子螯合剂后成骨细胞(hFOB1.19)膜铁转运蛋白1(FPN1)表达的变化,探讨铁离子浓度对成骨细胞FPN1表达的影响。方法将不同浓度的枸橼酸铁铵(FAC,50、100、200μmol/L)和去铁胺(DFO,5、10、20μmol/L)分别加入人hFOB1.19培养基,24h后用共聚焦显微镜(CLSM)测定细胞内铁离子浓度,用定量PCR、Westernblotting和免疫荧光法测定不同组别成骨细胞FPN1的表达并进行统计比较。结果用不同浓度的FAC和DFO干预20h后,成骨细胞内铁离子浓度随FAC浓度增加而增加,随DFO浓度增加而降低,组间差异有统计学意义(P<0.05);FPN1基因和蛋白表达随FAC浓度增加而增加,随DFO浓度增加而降低,组间差异有统计学意义(P<0.05)。结论高铁环境可上调FPN1表达,低铁环境可下调FPN1表达。FPN1表达量的改变可有效维持成骨细胞内铁离子浓度的平衡。

引用

页码：264 / 270

页数：7

共 17 条

[1]

Iron homeostasis in osteoporosis and its clinical implications [J].

Li, G. F. ;

Pan, Y. Z. ;

Sirois, P. ;

Li, K. ;

Xu, Y. J. .

OSTEOPOROSIS INTERNATIONAL, 2012, 23 (10) :2403-2408

[2]

Nrf2 regulates ferroportin 1-mediated iron efflux and counteracts lipopolysaccharide-induced ferroportin 1 mRNA suppression in macrophages [J].

Harada, Nobuhiko ;

Kanayama, Masaya ;

Maruyama, Atsushi ;

Yoshida, Aruto ;

Tazumi, Kyoko ;

Hosoya, Tomonori ;

Mimura, Junsei ;

Toki, Tsutomu ;

Maher, Jonathan M. ;

Yamamoto, Masayuki ;

Itoh, Ken .

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2011, 508 (01) :101-109

[3]

Iron chelator deferoxamine alters iron-regulatory genes and proteins and suppresses osteoblast phenotype in fetal rat calvaria cells [J].

Messer, Jonathan G. ;

Cooney, Paula T. ;

Kipp, Deborah E. .

BONE, 2010, 46 (05) :1408-1415

[4]

Iron overload alters iron-regulatory genes and proteins, down-regulates osteoblastic phenotype, and is associated with apoptosis in fetal rat calvaria cultures [J].

Messer, Jonathan G. ;

Kilbarger, Amy K. ;

Erikson, Keith M. ;

Kipp, Deborah E. .

BONE, 2009, 45 (05) :972-979

[5]

Excess iron inhibits osteoblast metabolism.[J].Kanako Yamasaki;Hiromi Hagiwara.Toxicology Letters.2009, 2

[6]

Differing expression of genes involved in non-transferrin iron transport across plasma membrane in various cell types under iron deficiency and excess [J].

Kamila Balusikova ;

Jitka Neubauerova ;

Marketa Dostalikova-Cimburova ;

Jiri Horak ;

Jan Kovar .

Molecular and Cellular Biochemistry, 2009, 321 :123-133

[7]

Therapeutic Effects of an Oral Chelator Targeting Skeletal Tissue Damage in Experimental Postmenopausal Osteoporosis in Rats*.[J].Gang Liu;Ping Men;Gerry H. Kenner;Scott C. Miller.Hemoglobin.2008, 1-2

[8]

Age-associated iron accumulation in bone: Implications for postmenopausal osteoporosis and a new target for prevention and treatment by chelation [J].